Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest neurodegenerative diseases Stories

2014-04-24 10:52:56

TAU discovers that protein clusters implicated in neurodegenerative diseases actually serve to protect brain cells People diagnosed with Huntington's disease, most in their mid-thirties and forties, face a devastating prognosis: complete mental, physical, and behavioral decline within two decades. "Mutant" protein clusters, long blamed for the progression of the genetic disease, have been the primary focus of therapies in development by pharmaceutical companies. But according to new...

2014-04-22 12:09:23

Research published in the Journal of Molecular Biology Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases. These molecules are based on what the Company calls a general amyloid interaction motif, or GAIM, which recognizes a characteristic common to many toxic, misfolded proteins, not just...

2014-04-22 08:30:14

--Research Published in the Journal of Molecular Biology-- CAMBRIDGE, Mass., April 22, 2014 /PRNewswire/ -- Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases. These molecules are based on what the Company calls a general amyloid interaction motif, or GAIM, which recognizes a...

2014-03-25 08:31:05

--Funds Will Advance Novel Approach for Treatment of Alzheimer's Disease and Other Diseases of Protein Aggregation-- CAMBRIDGE, Mass., March 25, 2014 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced the completion of a $17 million Series D financing from existing and new investors to advance the Company's lead candidate, NPT088, and potential next-generation compounds toward clinical trials. NPT088 has the potential to treat a wide range of neurodegenerative diseases,...

2014-01-31 12:25:20

U.S. Sen. Charles E. Schumer Helps Commemorate Opening of Building that Nearly Doubles Medical College's Research Space, Enhances Student Education NEW YORK, Jan. 31, 2014 /PRNewswire/ -- Weill Cornell Medical College today opened the Belfer Research Building, a state-of-the-art facility that ushers in a new era at the institution for cutting-edge, translational science. The 18-story, $650 million building, made possible through the generosity of numerous donors, nearly doubles Weill...

Pesticide Banned In The USA Linked To Alzheimer's Disease
2014-01-29 07:46:56

Rebekah Eliason for redOrbit.com – Your Universe Online For over 40 years scientists have recognized that DDT, a synthetic pesticide, harms bird habitats and is a threat to the environment. Although DDT was banned in the United States in 1972, other countries continue to use it as a pesticide. According to a new study from Rutgers University, exposure to DDT may cause increased risk and severity of Alzheimer’s disease. This is particularly true for people over 60 years of age. As...

2013-12-27 10:35:21

Researchers at Oregon Health & Science University have discovered that an antioxidant designed by scientists more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like disease. The antioxidant — called MitoQ — has shown some promise in fighting neurodegenerative diseases. But this is the first time it has been shown to significantly reverse an MS-like disease in an animal. The discovery could lead to an...

2013-12-19 08:28:23

- Novel Approach to Target Disease-driving Misfolded Proteins - CAMBRIDGE, Mass., Dec. 19, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced that it has been awarded an $822,000 grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF) for its second-generation drug candidate, NPT088, based on NeuroPhage's GAIM (general amyloid interaction motif) platform, which simultaneously targets multiple misfolded proteins central to many neurodegenerative...

2013-10-22 08:33:03

Fully Integrated Gene Therapy Company with Deep Clinical Pipeline Spun out of The Children's Hospital of Philadelphia PHILADELPHIA, Oct. 22, 2013 /PRNewswire/ -- Spark Therapeutics, a new, fully integrated company developing gene-based medicines for a wide range of debilitating diseases, announced today it has launched with a $50 million capital commitment from The Children's Hospital of Philadelphia (CHOP) to advance and commercialize multiple ongoing programs with clinical proof of...

2013-07-10 12:37:46

Presence of vascular disease reported across different neurodegenerative diseases Researchers in the Perelman School of Medicine at the University of Pennsylvania found that, across a variety of neurodegenerative diseases, cerebrovascular disease affecting circulation of blood in the brain was significantly associated with dementia. The researchers contend that people already exhibiting clinical features of Alzheimer's disease and other memory impairments may benefit from effective...